Suppr超能文献

伴有新导管生成的乳腺癌:组织病理学标准及其与乳腺X线摄影和肿瘤特征的相关性。

Breast cancer with neoductgenesis: histopathological criteria and its correlation with mammographic and tumour features.

作者信息

Zhou Wenjing, Sollie Thomas, Tot Tibor, Pinder Sarah E, Amini Rose-Marie, Blomqvist Carl, Fjällskog Marie-Louise, Christensson Gunilla, Abdsaleh Shahin, Wärnberg Fredrik

机构信息

Department of Surgical Sciences, Uppsala University, 751 85 Uppsala, Sweden.

Department of Pathology, Örebro University, 701 85 Örebro, Sweden.

出版信息

Int J Breast Cancer. 2014;2014:581706. doi: 10.1155/2014/581706. Epub 2014 Oct 8.

Abstract

Introduction. Breast cancer with mammographic casting type calcifications, high grade DCIS with an abnormal number of ducts, periductal desmoplastic reaction, lymphocyte infiltration, and tenascin-C (TN-C) overexpression has been proposed to represent a more aggressive form of breast cancer and has been denominated as breast cancer with neoductgenesis. We developed histopathological criteria for neoductgenesis in order to study reproducibility and correlation with other tumour markers. Methods. 74 cases of grades 2 and 3 DCIS, with or without an invasive component, were selected. A combined score of the degree(s) of concentration of ducts, lymphocyte infiltration, and periductal fibrosis was used to classify cases as showing neoductgenesis, or not. Diagnostic reproducibility, correlation with tumour markers, and mammographic features were studied. Results. Twenty-three of 74 cases were diagnosed with neoductgenesis. The kappa value between pathologists showed moderate reproducibility (0.50) (95% CI; 0.41-0.60). Neoductgenesis correlated significantly with malignant type microcalcifications and TN-C expression (P = 0.008 and 0.04) and with ER, PR, and HER2 status (P < 0.00001 for all three markers). Conclusions. We developed histological criteria for breast cancer with neoductgenesis. Neoductgenesis, by our applied histopathological definition was related to more aggressive tumour biology and malignant mammographic calcifications.

摘要

引言。乳腺钼靶显示铸型钙化的乳腺癌、伴有异常数量导管的高级别导管原位癌(DCIS)、导管周围促纤维增生反应、淋巴细胞浸润以及腱生蛋白-C(TN-C)过表达,被认为代表了一种侵袭性更强的乳腺癌形式,并被命名为伴有新导管生成的乳腺癌。我们制定了新导管生成的组织病理学标准,以研究其可重复性以及与其他肿瘤标志物的相关性。方法。选取74例2级和3级DCIS病例,有或无浸润成分。采用导管密集程度、淋巴细胞浸润程度和导管周围纤维化程度的综合评分,将病例分为显示新导管生成或不显示新导管生成。研究诊断的可重复性、与肿瘤标志物的相关性以及钼靶特征。结果。74例病例中有23例被诊断为新导管生成。病理学家之间的kappa值显示出中等可重复性(0.50)(95%可信区间;0.41 - 0.60)。新导管生成与恶性微钙化和TN-C表达显著相关(P = 0.008和0.04),与雌激素受体(ER)、孕激素受体(PR)和人表皮生长因子受体2(HER2)状态也显著相关(所有三种标志物P < 0.00001)。结论。我们制定了伴有新导管生成的乳腺癌的组织学标准。根据我们应用的组织病理学定义,新导管生成与更具侵袭性的肿瘤生物学特性和恶性钼靶钙化相关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d93c/4220584/64c557132587/IJBC2014-581706.001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验